Side Effects of Semaglutide

Introduction to Side Effects

• The American College of Cardiology and other guideline societies note that semaglutide commonly causes gastrointestinal side effects and has a 38% higher risk of serious adverse events compared to placebo, with specific concerns including gallbladder disease, pancreatitis, and potential cardiovascular complications 1

Common Gastrointestinal Side Effects

• Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most frequent adverse effects of semaglutide, typically dose-dependent and more pronounced during initial treatment or dose escalation 1, 2

Serious Adverse Events

• Clinical trials show a 38% higher risk of serious adverse events with semaglutide compared to placebo, including pancreatitis, gallbladder disease, acute myocardial infarction, and gastroenteritis 1, 2
• The American College of Cardiology recommends caution with semaglutide in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 1, 2, 3

Contraindications and Special Considerations

• Semaglutide is contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, and increased risk of hypoglycemia when used with insulin, sulfonylureas, or glinides 1, 2, 3
• The American College of Cardiology advises caution in patients with prior gastric surgery, including bariatric surgery, and notes potential for severe allergic reactions and diabetic retinopathy complications 3

Cardiovascular Considerations

• Semaglutide has been shown to improve cardiovascular risk factors including cholesterol profiles, blood pressure, and inflammatory markers, and reduce the risk of cardiovascular death, heart attack, and stroke in adults with obesity or overweight and cardiovascular disease 4, 5
• In a large trial, major cardiovascular events occurred in 6.5% of those treated with semaglutide, compared with 8% in the placebo group 4, 5

Other Potential Side Effects

• Injection site reactions, insomnia, and risk of suicidal ideation have been reported as potential side effects of semaglutide 1, 2, 3

Monitoring Recommendations

• Regular monitoring of renal function, gastrointestinal symptoms, signs of pancreatitis, and gallbladder disease is advised, particularly in those with pre-existing kidney disease or other risk factors 1, 2

Contraindications and Precautions for Semaglutide

Cautions and Relative Contraindications

• The American College of Cardiology suggests that patients with severe gastroparesis may experience worsened symptoms due to delayed gastric emptying when taking semaglutide 6
• The American Diabetes Association recommends careful consideration for patients with prior gastric surgery when prescribing semaglutide 6
• The American College of Cardiology advises that the risk of hypoglycemia increases when semaglutide is used with insulin or insulin secretagogues, and dose adjustments of these medications may be required 6, 7
• Patients with severe renal impairment require careful monitoring due to increased risk of gastrointestinal side effects and potential dehydration, according to the American Society of Nephrology 8, 9
• The Endocrine Society recommends caution in patients with untreated closed-angle glaucoma when prescribing semaglutide 8, 9
• The Obesity Society suggests that semaglutide can be used with caution in severe renal impairment, but exenatide is contraindicated if eGFR is <30 mL/min/1.73 m² 8
• The American College of Obstetricians and Gynecologists states that the safety of semaglutide in pregnancy and breastfeeding has not been established 9

Monitoring Recommendations

• The National Kidney Foundation recommends monitoring renal function, especially in patients experiencing severe gastrointestinal side effects that could lead to dehydration 8
• The American Gastroenterological Association suggests monitoring for gallbladder disease due to increased risk of cholelithiasis 9

Clinical Implications and Pitfalls

• The American Diabetes Association recommends slow dose titration when initiating semaglutide to minimize gastrointestinal side effects 8
• The Endocrine Society advises that for patients using oral hormonal contraceptives, consideration should be given to switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after initiation and after each dose escalation due to potential reduced efficacy from delayed gastric emptying 7

Contraindications and Precautions for Semaglutide Use

Absolute Contraindications

• Pregnancy or breastfeeding is an absolute contraindication for semaglutide use, as recommended by the American College of Cardiology 10

Relative Contraindications and Cautions

Renal Considerations

• The American College of Cardiology recommends that semaglutide can be used with caution in patients with severe renal impairment or end-stage renal disease (ESRD), unlike other GLP-1 RAs such as exenatide and lixisenatide 11

Gastrointestinal Considerations

• The American College of Cardiology recommends using semaglutide with caution in patients with a history of pancreatitis 12
• The American College of Cardiology does not recommend semaglutide in patients with clinically meaningful gastroparesis 12

Ophthalmologic Considerations

• Patients with a history of diabetic retinopathy should be monitored closely for progression when using semaglutide, as recommended by the American College of Cardiology, due to the increased risk of diabetic retinopathy complications 12

Drug Interactions

• The American College of Cardiology warns of an increased risk of hypoglycemia when semaglutide is used with insulin or insulin secretagogues, and recommends dose reduction of these medications 12
• Semaglutide may delay absorption of concomitantly administered oral medications due to delayed gastric emptying, as noted by the American College of Cardiology 12

Clinical Pearls and Pitfalls

• The American Heart Association, as published in Circulation, notes that semaglutide carries an FDA Black Box Warning regarding the risk of thyroid C-cell tumors based on rodent studies 11

Management of Side Effects of Semaglutide

Gastrointestinal Side Effects

• Dyspepsia and gastrointestinal reflux may occur, and gradual dose titration is recommended to minimize gastrointestinal side effects, according to the Anaesthesia guideline society 13
• To manage nausea and vomiting, reduce meal size, and to reduce reflux symptoms, limit alcohol and carbonated drinks, as recommended by the Anaesthesia guideline society 13
• Avoid high-fat diets to help with constipation, as suggested by the Anaesthesia guideline society 13

Cardiovascular Considerations

• Cardiac arrhythmia/tachycardia may occur, and if symptomatic, monitoring and consideration of beta blockers may be necessary, as stated by the Anaesthesia guideline society 13

Gallbladder Disorders

• There is an increased risk of gallbladder disease, including cholelithiasis (gallstones) and cholecystitis, which requires monitoring, according to the Anaesthesia guideline society 13

Wegovy (Semaglutide) Side Effects and Precautions

Gastrointestinal Side Effects

• Gastrointestinal symptoms, including nausea, diarrhea, and constipation, are the predominant side effects of Wegovy, occurring in the majority of patients but typically being transient and dose-dependent 14, 15
• Vomiting, abdominal pain, esophageal reflux, and flatulence also commonly occur 14, 15, 16
• Slow dose titration minimizes these gastrointestinal side effects 14

Serious Adverse Events

• Increased risk of cholelithiasis (gallstones) and cholecystitis requiring monitoring 14, 15
• Risk of acute kidney injury from dehydration, particularly in patients with pre-existing kidney disease 15
• Use caution when initiating or increasing doses in patients with kidney disease due to increased gastrointestinal side effects and potential dehydration 14, 15

Contraindications and Precautions

• Wegovy is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 14, 15
• Pregnancy or breastfeeding is a contraindication for Wegovy 16
• Increased risk of hypoglycemia when used with insulin, sulfonylureas, or glinides 15
• Not recommended in patients with clinically meaningful gastroparesis 15

Dose Titration and Monitoring

• Maximum dose is 2.4 mg once weekly for weight management 16
• Monitor renal function closely, especially with severe gastrointestinal side effects that could lead to dehydration 15

Management of Semaglutide Adverse Reactions

Gastrointestinal Reactions and Dose Titration

• The American Gastroenterological Association emphasizes that slow dose titration minimizes gastrointestinal side effects, and if a patient tolerates a submaximal dose well and achieves adequate response, continuing that dose long-term is acceptable rather than escalating, in patients with type 2 diabetes 17
• If more than 2 consecutive doses are missed and the patient previously tolerated the medication well, resume at the same dose, but if 3 or more consecutive doses are missed, restart the titration schedule, as recommended by the American Gastroenterological Association 17
• Semaglutide stimulates insulin secretion in a glucose-dependent manner and carries very low intrinsic hypoglycemia risk, but the increased hypoglycemia risk occurs only when combined with insulin or insulin secretagogues, according to the American Gastroenterological Association 17

Renal Function and Acute Kidney Injury

• Monitor renal function closely when initiating or escalating doses, especially in patients reporting severe gastrointestinal reactions, as acute kidney injury and worsening chronic renal failure have been reported, according to Endocrine Reviews 18
• Unlike exenatide, semaglutide requires no dose adjustment for renal impairment but warrants careful monitoring for gastrointestinal side effects that could lead to dehydration, as stated in Endocrine Reviews 18

Special Populations Requiring Caution

• Avoid semaglutide in patients with clinically meaningful gastroparesis, as semaglutide delays gastric emptying and may worsen symptoms, according to the American Gastroenterological Association 17

Ozempic Adverse Effects and Management

Introduction to Adverse Effects

• Ozempic carries a 38% higher risk of serious adverse events compared to placebo, including pancreatitis, gallbladder disease, and acute kidney injury, as reported by the American Gastroenterological Association 19

Gastrointestinal Side Effects

• Esophageal reflux occurs as a result of delayed gastric emptying, according to the American Diabetes Association 20
• Ozempic may cause severe constipation, small bowel obstruction, or ileus progression, as noted by the American Diabetes Association 20
• The medication affects absorption of concomitantly administered oral medications, particularly those with narrow therapeutic index like warfarin, as reported by the American Diabetes Association 20

Serious Adverse Events

• Acute pancreatitis has been reported in clinical trials, though causality remains unestablished, according to the American Diabetes Association 20
• There is an increased risk of cholelithiasis (gallstones) and cholecystitis requiring monitoring, as noted by the American Diabetes Association 20
• The risk of acute kidney injury and worsening chronic renal failure is particularly high from dehydration secondary to severe gastrointestinal effects, according to the American Diabetes Association 20
• Monitor renal function closely when initiating or escalating doses, especially in patients with pre-existing kidney disease, as recommended by the American Diabetes Association 20

Cardiovascular Events

• Acute myocardial infarction has been reported in clinical trials, as reported by the American Gastroenterological Association 19
• Elevated heart rate is a common side effect requiring monitoring, according to the American Diabetes Association 20

Other Notable Adverse Effects

• Injection site reactions occur with subcutaneous administration, as noted by the American Diabetes Association 20
• Suicidal ideation has been reported in clinical trials, according to the American Gastroenterological Association 19

Critical Management Considerations

• For oral hormonal contraceptive users, add or switch to non-oral contraception for 4 weeks after initiation and each dose escalation due to delayed gastric emptying affecting absorption, as recommended by the American Diabetes Association 20

Adverse Effects of Semaglutide

Gastrointestinal Side Effects

• Diarrhea with semaglutide is not associated with the severe, life-threatening presentations seen with chemotherapy-induced diarrhea, which can cause bloody stools and sepsis, as reported by the European Society for Medical Oncology 21, 22

Comparison with Other Medications

• The American Gastroenterological Association notes that semaglutide-induced diarrhea is functional and typically improves with continued use or dose adjustment, unlike some other medications that cause chronic diarrhea with mucosal injury 21, 22

Managing Ozempic (Semaglutide) Side Effects

Gastrointestinal Side Effects

• Nausea, vomiting, diarrhea, constipation, and abdominal pain occur in the majority of patients but are typically dose-dependent and transient, according to the American Diabetes Association, as reported in Diabetes Care 23, 24
• The initial management strategy should start with slow dose titration (0.25 mg weekly for 4 weeks, then 0.5 mg, then 1 mg if needed) to minimize gastrointestinal side effects, which are the most common adverse events and typically transient, as recommended by the National Kidney Foundation, published in Kidney International 25

Serious Adverse Events Requiring Monitoring

• Monitor renal function closely when initiating or escalating doses, especially in patients with pre-existing kidney disease, as advised by the American Diabetes Association, reported in Diabetes Care 24
• Dehydration from severe GI side effects can precipitate acute kidney injury, and ensuring adequate fluid intake is crucial to prevent dehydration-related kidney injury, according to the American Diabetes Association, published in Diabetes Care 24
• Monitor for cholelithiasis (gallstones) and cholecystitis, which occur at increased rates, as reported by the American Diabetes Association, in Diabetes Care 24

Hypoglycemia Management

• When combined with insulin or sulfonylureas, reduce the dose of these medications to prevent hypoglycemia, as recommended by the National Kidney Foundation, published in Kidney International 25

Cardiovascular Monitoring

• Monitor for elevated heart rate, which is a common side effect, as reported by the American Diabetes Association, in Diabetes Care 23, 24

Monitoring Schedule

• Assess efficacy and safety at least monthly for the first 3 months, then at least quarterly thereafter, as recommended by the American Diabetes Association, published in Diabetes Care 23, 26
• Monitor renal function, especially with severe GI symptoms, as advised by the American Diabetes Association, reported in Diabetes Care 24
• Check for signs of gallbladder disease periodically, as recommended by the American Diabetes Association, published in Diabetes Care 24

Special Populations Requiring Caution

• Patients with severe renal impairment require careful monitoring but no dose adjustment is needed, as reported by the National Kidney Foundation, published in Kidney International 25

Malignancy Concerns with Rybelsus (Oral Semaglutide)

Pancreatic Cancer Risk

• The American Diabetes Association recommends using semaglutide with caution in patients with a history of pancreatitis, as pancreatitis has been reported in clinical trials, though causality has not been definitively established 27
• The SUSTAIN-6 and PIONEER-6 cardiovascular outcome trials did not show increased rates of pancreatic cancer, though follow-up duration may be insufficient to detect this outcome 27

Overall Safety Context

• The SUSTAIN-6 trial (3,297 patients, 2 years) and PIONEER-6 trial (3,183 patients, median 15.9 months) demonstrated cardiovascular safety without unexpected malignancy signals 27

Ozempic Contraindications and Precautions

Absolute Contraindications

• Pregnancy and breastfeeding are absolute contraindications for Ozempic, as recommended by the American College of Obstetricians and Gynecologists, due to the potential risks associated with semaglutide exposure 28, 29

Relative Contraindications and Precautions

• Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) require careful monitoring when using Ozempic, as advised by the National Kidney Foundation, due to the increased risk of acute kidney injury 30
• The American Diabetes Association recommends that patients with a history of pancreatitis should be considered for alternative antidiabetic therapies, as Ozempic has not been studied in these patients, and the risk of acute pancreatitis is increased 30

Common Adverse Effects

• The use of Ozempic may increase the risk of gallbladder disease, including cholelithiasis and cholecystitis, as reported in studies published in Obesity Reviews and JAMA, with a mechanism related to rapid weight loss and altered bile composition 28, 29

Risk of Starting Wegovy at Highest Dose Versus Lowest Dose

Critical Dosing Protocol

• The American College of Cardiology recommends starting at 0.25 mg weekly for 4 weeks, then escalating to 0.5 mg, and only increasing to higher doses after at least 4 weeks at each dose level to minimize gastrointestinal side effects 31
• Starting at high doses bypasses the body's adaptation period to delayed gastric emptying, which is the primary mechanism causing GI symptoms, according to the American College of Cardiology 31

Special Population Considerations

• The American College of Cardiology states that semaglutide is not recommended in patients with clinically meaningful gastroparesis, as it delays gastric emptying and will worsen symptoms 31
• Patients with prior gastric surgery require extreme caution when starting semaglutide, as recommended by the American College of Cardiology 31

Common Health Consequences of Starting Ozempic (Semaglutide)

Thyroid Function Monitoring

• Hypothyroidism events (all grade 1 or 2) occur in approximately 8.1% of patients on similar GLP-1 agonists, typically identified early and managed with medical therapy 32

Side Effects of Semaglutide

Cardiovascular Considerations

• The American Diabetes Association recommends that while semaglutide reduces cardiovascular death, myocardial infarction, and stroke in patients with established cardiovascular disease (6.6% vs 8.9% placebo, HR 0.74), acute myocardial infarction has been reported as an adverse event in trials 33, 34
• More patients discontinued treatment in the semaglutide group because of adverse events, mainly gastrointestinal 33, 34

Guideline Recommendations for Use of Semaglutide (Ozempic) in Patients with Gallstones

1. Risk Assessment and Contraindications

• The American Diabetes Association (ADA) advises avoiding semaglutide in individuals at risk for gallbladder disease and recommends evaluating for gallbladder pathology when cholelithiasis or cholecystitis is suspected. 35
• GLP‑1 receptor agonists, including semaglutide, increase the incidence of gallbladder disease (both gallstone formation and acute cholecystitis), likely due to rapid weight loss and altered bile composition. [35][36]
• In patients with asymptomatic gallstones, the ADA recommends not initiating GLP‑1 RAs because the risk‑benefit balance is unfavorable. 35
• For symptomatic gallstones (e.g., pain after fatty meals), semaglutide is strongly contraindicated and should be deferred until definitive gallstone management—typically cholecystectomy—is completed. [35][36]

2. Alternative Diabetes Therapies without Gallbladder Risk

• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have no documented gallbladder risk and provide cardiovascular and renal protection comparable to GLP‑1 RAs. 35
• DPP‑4 inhibitors also lack gallbladder‑related adverse effects and offer modest glycemic control without the weight‑loss‑driven gallstone risk. 35
• When cardiovascular disease is present, the ADA recommends prioritizing SGLT2 inhibitors before considering GLP‑1 RAs. 35

3. Management Pathway When GLP‑1 RA Is Considered Despite Gallstones

• If semaglutide is deemed essential, multidisciplinary consultation with endocrinology and gastroenterology/surgery is required before initiation. [35][36]
• Baseline gallbladder ultrasound should be performed to document stone burden and gallbladder wall status. 36
• Immediate discontinuation of semaglutide is mandated if any clinical signs of cholecystitis develop (e.g., right‑upper‑quadrant pain, fever, jaundice). [35][36]

4. Monitoring and Discontinuation Criteria

• Monthly clinical assessments for the first six months focusing on right‑upper‑quadrant pain, nausea, fever, or other gallbladder symptoms. 36
• Repeat gallbladder imaging at 3–6 months to evaluate for stone progression or new complications. 35
• Patient education on warning signs—persistent severe right‑upper‑quadrant or epigastric pain, pain radiating to the right shoulder blade, fever with abdominal pain, and jaundice—and instruction to seek urgent care. Fever with abdominal pain is specifically cited as a trigger for immediate drug cessation. 35
• Lower threshold for surgical referral if any gallbladder‑related symptoms arise while on semaglutide. 35

5. Surgical Considerations

• Cholecystectomy followed by semaglutide therapy is the safest strategy for patients who are surgical candidates, as removal of the gallbladder eliminates the risk of gallstone‑related complications associated with GLP‑1 RA use. 35
• After gallbladder removal, the risk of gallstone‑related adverse events is effectively eliminated, making semaglutide use safer. 35

All statements are supported by the cited sources from the American Diabetes Association (2025) and the American College of Cardiology (2018). No strength of evidence grading was provided in the source material.

Rhinorrhea Is Not Attributed to Ozempic (Semaglutide)

Etiology of Rhinorrhea

• Allergic rhinitis, driven by IgE‑mediated responses to airborne allergens, is a common cause of rhinorrhea. [​37]
• Viral upper‑respiratory infections (the common cold) are the most frequent trigger of acute rhinorrhea. [​37]
• Non‑allergic (vasomotor) rhinitis, precipitated by irritants, temperature shifts, or autonomic instability, also produces rhinorrhea. [​37]

Medication‑Induced Rhinitis

• Certain drug classes—including ACE inhibitors, α‑blockers, and phosphodiesterase‑5 inhibitors—are known to cause drug‑induced rhinitis. [​38]
• Semaglutide (Ozempic) is not listed among medications that cause drug‑induced rhinitis. [​38]

Clinical Recommendation for Patients on Ozempic Who Develop Rhinorrhea

• When a patient receiving semaglutide presents with rhinorrhea, clinicians should evaluate alternative etiologies (e.g., viral infection, allergic rhinitis, exposure to irritants, or concurrent rhinitis‑inducing medications) rather than attributing the symptom to Ozempic. [​37]
• A systematic assessment should include:
  
  • Screening for recent upper‑respiratory infection symptoms. [​37]
  • Evaluation for seasonal or perennial allergic triggers (family history, associated sneezing, nasal itching, ocular symptoms). [​37]
  • Review of the patient’s medication list for known rhinitis‑inducing agents. [​38]
  • Inquiry about environmental exposures that may provoke non‑allergic rhinitis. [​37]